Tirzepatide

Average weight loss on tirzepatide from SURMOUNT-1 (Jastreboff et al.

Introduction Compounded tirzepatide is the same dual GIP/GLP-1 agonist molecule as Mounjaro® and Zepbound®, made by licensed 503A or 503B pharmacies and dispensed through…

Tirzepatide is a dual incretin agonist. It binds and activates both the GIP receptor and the GLP-1 receptor with engineered selectivity.

Compounded tirzepatide is legal in all 50 states when a state-licensed 503A pharmacy prepares it for a specific patient with a valid prescription.

Tirzepatide’s clinical footprint has expanded rapidly.

Introduction The FDA-approved eligibility for tirzepatide (Zepbound®) for weight management is BMI ≥30 (obesity) or BMI ≥27 (overweight) with at least one weight-related condition…

Tirzepatide has relatively few clinically significant drug interactions.

Tirzepatide follows a 6-step titration over about 20-24 weeks: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly, each step held for four weeks.

Introduction Compounded tirzepatide arrives either as a pre-mixed liquid in a glass vial or as a freeze-dried powder that the patient reconstitutes at home…